JP2018525377A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525377A5 JP2018525377A5 JP2018506125A JP2018506125A JP2018525377A5 JP 2018525377 A5 JP2018525377 A5 JP 2018525377A5 JP 2018506125 A JP2018506125 A JP 2018506125A JP 2018506125 A JP2018506125 A JP 2018506125A JP 2018525377 A5 JP2018525377 A5 JP 2018525377A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- phenyl
- pyrrolo
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 40
- 125000003118 aryl group Chemical group 0.000 claims 38
- 125000000623 heterocyclic group Chemical group 0.000 claims 35
- -1 —OH Chemical group 0.000 claims 34
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000002950 monocyclic group Chemical group 0.000 claims 18
- 229910052799 carbon Inorganic materials 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 8
- 125000004452 carbocyclyl group Chemical group 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 5
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- JPFAOFJABONAJB-VHSZZVNMSA-N 2-[5-[(3R,4R,6S)-11-fluoro-3-(2-phenoxyphenyl)-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrimidin-2-yl]propan-2-ol Chemical compound FC=1C(=CC2=C(N=C3N2[C@H]([C@H]2[C@@H]3C2)C2=C(C=CC=C2)OC2=CC=CC=C2)C=1)C=1C=NC(=NC=1)C(C)(C)O JPFAOFJABONAJB-VHSZZVNMSA-N 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 3
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- ZMXXUTYAIDYCHN-TYBLODHISA-N 1-[(10R,14S,15S)-4-(6-methoxypyridin-3-yl)-15-phenyl-1,8,12-triazatetracyclo[7.6.0.02,7.010,14]pentadeca-2(7),3,5,8-tetraen-12-yl]ethanone Chemical compound COC1=CC=C(C=N1)C1=CC2=C(N=C3N2[C@@H]([C@H]2[C@@H]3CN(C2)C(C)=O)C2=CC=CC=C2)C=C1 ZMXXUTYAIDYCHN-TYBLODHISA-N 0.000 claims 2
- ZWWMMUMETQYJQW-JKSBSHDWSA-N 1-[4-[(3R,4S,6R)-3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrazol-1-yl]-2-methylpropan-2-ol Chemical compound FC(OC1=C(C=CC=C1)[C@H]1[C@@H]2[C@H](C=3N1C1=C(N=3)C=C(C(=C1)C=1C=NN(C=1)CC(C)(O)C)F)C2)F ZWWMMUMETQYJQW-JKSBSHDWSA-N 0.000 claims 2
- NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical compound NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 claims 2
- HRDJBRDUCRJPQF-GLDPYIMESA-N 2-[4-[(3R,4S,6R)-3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]phenyl]propan-2-ol Chemical compound FC(OC1=C(C=CC=C1)[C@H]1[C@@H]2[C@H](C=3N1C1=C(N=3)C=C(C(=C1)C1=CC=C(C=C1)C(C)(C)O)F)C2)F HRDJBRDUCRJPQF-GLDPYIMESA-N 0.000 claims 2
- OOFCGIVGOQCKFA-CEYNDMKZSA-N 2-[4-[5-[(3R,4S,6R)-3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrimidin-2-yl]piperazin-1-yl]acetic acid Chemical compound FC(OC1=C(C=CC=C1)[C@H]1[C@@H]2[C@H](C=3N1C1=C(N=3)C=C(C(=C1)C=1C=NC(=NC=1)N1CCN(CC1)CC(=O)O)F)C2)F OOFCGIVGOQCKFA-CEYNDMKZSA-N 0.000 claims 2
- OOFCGIVGOQCKFA-HHJKRLRDSA-N 2-[4-[5-[(3S,4R,6S)-3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrimidin-2-yl]piperazin-1-yl]acetic acid Chemical compound FC(OC1=C(C=CC=C1)[C@@H]1[C@H]2[C@@H](C=3N1C1=C(N=3)C=C(C(=C1)C=1C=NC(=NC=1)N1CCN(CC1)CC(=O)O)F)C2)F OOFCGIVGOQCKFA-HHJKRLRDSA-N 0.000 claims 2
- JIQGOPATCHHCIY-JVAFGIKQSA-N 2-[5-[(3R,4R,6S)-11-fluoro-3-[2-(2-fluorophenoxy)phenyl]-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrimidin-2-yl]propan-2-ol Chemical compound FC=1C(=CC2=C(N=C3N2[C@H]([C@H]2[C@@H]3C2)C2=C(C=CC=C2)OC2=C(C=CC=C2)F)C=1)C=1C=NC(=NC=1)C(C)(C)O JIQGOPATCHHCIY-JVAFGIKQSA-N 0.000 claims 2
- SMBWSTQAPWTKBN-VHSZZVNMSA-N 2-[5-[(3R,4R,6S)-11-fluoro-3-[2-(pyridin-4-ylmethoxy)phenyl]-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrimidin-2-yl]propan-2-ol Chemical compound FC=1C(=CC2=C(N=C3N2[C@H]([C@H]2[C@@H]3C2)C2=C(C=CC=C2)OCC2=CC=NC=C2)C=1)C=1C=NC(=NC=1)C(C)(C)O SMBWSTQAPWTKBN-VHSZZVNMSA-N 0.000 claims 2
- ZEUSMNCNQXELPK-JWZKTCGFSA-N 2-[5-[(3R,4S,6R)-11-fluoro-3-(2-phenylmethoxyphenyl)-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrimidin-2-yl]propan-2-ol Chemical compound C(C1=CC=CC=C1)OC1=C(C=CC=C1)[C@H]1[C@@H]2[C@H](C=3N1C1=C(N=3)C=C(C(=C1)C=1C=NC(=NC=1)C(C)(C)O)F)C2 ZEUSMNCNQXELPK-JWZKTCGFSA-N 0.000 claims 2
- KPSZBWZVNHDONM-MFEFFIJZSA-N 2-[5-[(3R,4S,6R)-3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyridin-2-yl]propan-2-ol Chemical compound FC(OC1=C(C=CC=C1)[C@H]1[C@@H]2[C@H](C=3N1C1=C(N=3)C=C(C(=C1)C=1C=CC(=NC=1)C(C)(C)O)F)C2)F KPSZBWZVNHDONM-MFEFFIJZSA-N 0.000 claims 2
- DSEWTWHQTAWRCR-MRUHUIDDSA-N 2-[5-[(3R,4S,6R)-3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrimidin-2-yl]propan-2-ol Chemical compound FC(OC1=C(C=CC=C1)[C@H]1[C@@H]2[C@H](C=3N1C1=C(N=3)C=C(C(=C1)C=1C=NC(=NC=1)C(C)(C)O)F)C2)F DSEWTWHQTAWRCR-MRUHUIDDSA-N 0.000 claims 2
- JPFAOFJABONAJB-UMTXDNHDSA-N 2-[5-[(3S,4R,6S)-11-fluoro-3-(2-phenoxyphenyl)-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrimidin-2-yl]propan-2-ol Chemical compound FC=1C(=CC2=C(N=C3N2[C@@H]([C@H]2[C@@H]3C2)C2=C(C=CC=C2)OC2=CC=CC=C2)C=1)C=1C=NC(=NC=1)C(C)(C)O JPFAOFJABONAJB-UMTXDNHDSA-N 0.000 claims 2
- DSEWTWHQTAWRCR-UHFFFAOYSA-N 2-[5-[3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrimidin-2-yl]propan-2-ol Chemical compound CC(C)(C1=NC=C(C=N1)C2=CC3=C(C=C2F)N=C4N3C(C5C4C5)C6=CC=CC=C6OC(F)F)O DSEWTWHQTAWRCR-UHFFFAOYSA-N 0.000 claims 2
- QDNDBBUGYUSVSP-UHFFFAOYSA-N 3,6,10-triazatricyclo[6.3.0.02,6]undeca-1(11),2,4,7,9-pentaene Chemical compound N1=C2N(C=C1)C=C1C2=CN=C1 QDNDBBUGYUSVSP-UHFFFAOYSA-N 0.000 claims 2
- KNIBARYIKQDQLT-STSQHVNTSA-N 4-[5-[(3R,4R,6S)-3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrimidin-2-yl]morpholine Chemical compound FC(OC1=C(C=CC=C1)[C@H]1[C@H]2[C@@H](C=3N1C1=C(N=3)C=C(C(=C1)C=1C=NC(=NC=1)N1CCOCC1)F)C2)F KNIBARYIKQDQLT-STSQHVNTSA-N 0.000 claims 2
- KTPATMKWJBZRCF-IXFSTUDKSA-N 4-[5-[(3R,4S,6R)-3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrimidin-2-yl]-1,4-thiazinane 1,1-dioxide Chemical compound FC(OC1=C(C=CC=C1)[C@H]1[C@@H]2[C@H](C=3N1C1=C(N=3)C=C(C(=C1)C=1C=NC(=NC=1)N1CCS(CC1)(=O)=O)F)C2)F KTPATMKWJBZRCF-IXFSTUDKSA-N 0.000 claims 2
- KNIBARYIKQDQLT-IXFSTUDKSA-N 4-[5-[(3R,4S,6R)-3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrimidin-2-yl]morpholine Chemical compound FC(OC1=C(C=CC=C1)[C@H]1[C@@H]2[C@H](C=3N1C1=C(N=3)C=C(C(=C1)C=1C=NC(=NC=1)N1CCOCC1)F)C2)F KNIBARYIKQDQLT-IXFSTUDKSA-N 0.000 claims 2
- MNIYJLHJHQTSEE-MFEFFIJZSA-N 4-[5-[(3R,4S,6R)-3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyrimidin-2-yl]piperazin-2-one Chemical compound FC(OC1=C(C=CC=C1)[C@H]1[C@@H]2[C@H](C=3N1C1=C(N=3)C=C(C(=C1)C=1C=NC(=NC=1)N1CC(NCC1)=O)F)C2)F MNIYJLHJHQTSEE-MFEFFIJZSA-N 0.000 claims 2
- UYWCYWQJCZVXOE-DMPWYTOCSA-N 5-[(3R,4S,6R)-3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]-N-methylpyridine-2-carboxamide Chemical compound FC(OC1=C(C=CC=C1)[C@H]1[C@@H]2[C@H](C=3N1C1=C(N=3)C=C(C(=C1)C=1C=CC(=NC=1)C(=O)NC)F)C2)F UYWCYWQJCZVXOE-DMPWYTOCSA-N 0.000 claims 2
- QIJWWKSMZROLSE-JKSBSHDWSA-N 5-[(3R,4S,6R)-3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]pyridine-2-carbonitrile Chemical compound FC(OC1=C(C=CC=C1)[C@H]1[C@@H]2[C@H](C=3N1C1=C(N=3)C=C(C(=C1)C=1C=CC(=NC=1)C#N)F)C2)F QIJWWKSMZROLSE-JKSBSHDWSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- IPWXIRRQCOHHDM-BEYSDYMESA-N [(10R,14S,15S)-4-(6-methoxypyridin-3-yl)-15-phenyl-1,8,12-triazatetracyclo[7.6.0.02,7.010,14]pentadeca-2(7),3,5,8-tetraen-12-yl]-phenylmethanone Chemical compound COC1=CC=C(C=N1)C1=CC2=C(N=C3N2[C@@H]([C@H]2[C@@H]3CN(C2)C(=O)C2=CC=CC=C2)C2=CC=CC=C2)C=C1 IPWXIRRQCOHHDM-BEYSDYMESA-N 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- 238000010276 construction Methods 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- QMLWSAXEQSBAAQ-UHFFFAOYSA-N oxetan-3-ol Chemical compound OC1COC1 QMLWSAXEQSBAAQ-UHFFFAOYSA-N 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- REHZGGMEMKVABZ-GLDPYIMESA-N tert-butyl 4-[(3R,4S,6R)-3-[2-(difluoromethoxy)phenyl]-11-fluoro-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound FC(OC1=C(C=CC=C1)[C@H]1[C@@H]2[C@H](C=3N1C1=C(N=3)C=C(C(=C1)C=1CCN(CC=1)C(=O)OC(C)(C)C)F)C2)F REHZGGMEMKVABZ-GLDPYIMESA-N 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- GXORCHFZBANVBV-GKIKGMKOSA-N 5-[(3S,4R,5R,6S)-3-(2,5-dimethylphenyl)-5-phenyl-2,8-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),7,10,12-tetraen-12-yl]-N-methylpyridine-2-carboxamide Chemical compound CC1=C(C=C(C=C1)C)[C@@H]1[C@H]2[C@@H](C=3N1C1=C(N=3)C=CC(=C1)C=1C=CC(=NC=1)C(=O)NC)[C@@H]2C1=CC=CC=C1 GXORCHFZBANVBV-GKIKGMKOSA-N 0.000 claims 1
- NACQRCDPSHHQPT-UHFFFAOYSA-N 8-(6-methoxypyridin-3-yl)-11-phenyl-4,4a,11,11a-tetrahydro-1H-isoindolo[2,1-a]benzimidazole Chemical compound COc1ccc(cn1)-c1ccc2nc3C4CC=CCC4C(c4ccccc4)n3c2c1 NACQRCDPSHHQPT-UHFFFAOYSA-N 0.000 claims 1
- 235000011470 Adenanthera pavonina Nutrition 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 241000428378 Lopa Species 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200415P | 2015-08-03 | 2015-08-03 | |
| US62/200,415 | 2015-08-03 | ||
| PCT/US2016/045104 WO2017023902A1 (en) | 2015-08-03 | 2016-08-02 | Cyclic compounds useful as modulators of tnf alpha |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525377A JP2018525377A (ja) | 2018-09-06 |
| JP2018525377A5 true JP2018525377A5 (enExample) | 2019-08-15 |
| JP6811233B2 JP6811233B2 (ja) | 2021-01-13 |
Family
ID=56610045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506125A Active JP6811233B2 (ja) | 2015-08-03 | 2016-08-02 | Ｔｎｆアルファの修飾因子として有用な環状化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10335392B2 (enExample) |
| EP (1) | EP3331889B1 (enExample) |
| JP (1) | JP6811233B2 (enExample) |
| KR (1) | KR102679517B1 (enExample) |
| CN (1) | CN108137609B (enExample) |
| AU (1) | AU2016301215A1 (enExample) |
| BR (1) | BR112018001980A2 (enExample) |
| CA (1) | CA2994703A1 (enExample) |
| EA (1) | EA201890421A1 (enExample) |
| ES (1) | ES2828696T3 (enExample) |
| IL (1) | IL257159A (enExample) |
| MX (1) | MX2018001173A (enExample) |
| WO (1) | WO2017023902A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201706258A (zh) | 2015-04-17 | 2017-02-16 | 艾伯維有限公司 | 作為ｔｎｆ信號傳遞調節劑之吲唑酮 |
| AR104291A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| TW201702247A (zh) | 2015-04-17 | 2017-01-16 | 艾伯維有限公司 | 作為ｔｎｆ信號傳遞調節劑之吲唑酮 |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| AU2021268345A1 (en) | 2020-05-05 | 2022-11-10 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| WO2021226208A2 (en) | 2020-05-05 | 2021-11-11 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| KR20240087788A (ko) | 2021-10-01 | 2024-06-19 | 뉴베일런트, 아이엔씨. | 헤테로방향족 매크로사이클릭 에테르 화합물의 고체 형태, 약학 조성물 및 제조 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5149386A (ja) * | 1974-10-28 | 1976-04-28 | Hitachi Ltd | Shuchukanshiseigyohoho |
| JP2001513084A (ja) | 1997-02-25 | 2001-08-28 | ザ ガバメント オブ ザ ユナイテッド ステーツ オブ アメリカ，レプリゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシズ | 逆転写酵素の非ヌクレオシド阻害剤としての置換ベンズイミダゾール |
| JPH11228539A (ja) * | 1997-12-03 | 1999-08-24 | Taisho Pharmaceut Co Ltd | 含窒素四環性化合物 |
| US7601846B2 (en) | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
| JPWO2003064422A1 (ja) | 2002-01-31 | 2005-05-26 | 第一製薬株式会社 | イミダゾ［１，２−ａ］ピリジン誘導体 |
| AU2003298839A1 (en) | 2002-12-03 | 2004-06-23 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
| US20050124638A1 (en) | 2003-12-08 | 2005-06-09 | Swayze Eric E. | Benzimidazoles and analogs thereof as antivirals |
| US20110009403A1 (en) | 2007-10-05 | 2011-01-13 | S*Bio Pte Ltd. | 2-morpholinylpurines as inhibitors of pi3k |
| JP2009227599A (ja) | 2008-03-21 | 2009-10-08 | Daiichi Sankyo Co Ltd | イミダゾピリダジン誘導体 |
| CN101717397B (zh) | 2008-10-09 | 2012-11-28 | 中国科学院上海药物研究所 | 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物 |
| EP2411057B1 (en) | 2009-03-23 | 2020-05-06 | Eli Lilly and Company | Imaging agents for detecting neurological disorders |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| BR112015000675B1 (pt) | 2012-07-13 | 2022-07-12 | UCB Biopharma SRL | Derivados de imidazopiridina como moduladores da atividade de tnf |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| KR101669334B1 (ko) * | 2013-09-30 | 2016-10-25 | 주식회사 엘지화학 | 헤테로환 화합물 및 이를 포함하는 유기 발광 소자 |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| JP6469692B2 (ja) | 2013-12-09 | 2019-02-13 | ユーシービー バイオファルマ エスピーアールエル | Ｔｎｆ活性のモジュレーターとしてのイミダゾピリジン誘導体 |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321745D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| CN105814022B (zh) | 2013-12-09 | 2018-09-28 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合的二环杂芳族衍生物 |
| GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| EA201790779A1 (ru) | 2014-10-06 | 2017-09-29 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений |
| US10308652B2 (en) | 2015-03-18 | 2019-06-04 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds useful as inhibitors of TNF |
| ES2803650T3 (es) | 2015-03-18 | 2021-01-28 | Bristol Myers Squibb Co | Compuestos heterocíclicos útiles como inhibidores de TNF |
| SG11201707469WA (en) | 2015-03-18 | 2017-10-30 | Bristol Myers Squibb Co | Substituted tricyclic heterocyclic compounds |
-
2016
- 2016-08-02 AU AU2016301215A patent/AU2016301215A1/en not_active Abandoned
- 2016-08-02 ES ES16748045T patent/ES2828696T3/es active Active
- 2016-08-02 CN CN201680057965.1A patent/CN108137609B/zh active Active
- 2016-08-02 US US15/749,611 patent/US10335392B2/en active Active
- 2016-08-02 MX MX2018001173A patent/MX2018001173A/es unknown
- 2016-08-02 CA CA2994703A patent/CA2994703A1/en not_active Abandoned
- 2016-08-02 KR KR1020187005708A patent/KR102679517B1/ko active Active
- 2016-08-02 WO PCT/US2016/045104 patent/WO2017023902A1/en not_active Ceased
- 2016-08-02 EP EP16748045.8A patent/EP3331889B1/en active Active
- 2016-08-02 BR BR112018001980A patent/BR112018001980A2/pt not_active Application Discontinuation
- 2016-08-02 EA EA201890421A patent/EA201890421A1/ru unknown
- 2016-08-02 JP JP2018506125A patent/JP6811233B2/ja active Active
-
2018
- 2018-01-25 IL IL257159A patent/IL257159A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525377A5 (enExample) | ||
| JP7505023B2 (ja) | 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤 | |
| US11420958B2 (en) | Aryl and heteroaryl substituted indole compounds | |
| US10669269B2 (en) | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | |
| JP5997335B2 (ja) | Ｎ含有複素環式化合物 | |
| AU2011242778B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| AU2019283921A1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| JP2020514267A5 (enExample) | ||
| US20200392161A1 (en) | Shp2 phosphatase inhibitors and methods of use thereof | |
| AU2019257450A1 (en) | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors | |
| FI3932919T3 (fi) | Jak-inhibiittoriyhdiste ja sen käyttö | |
| JP2012519678A5 (enExample) | ||
| JP2018500376A5 (enExample) | ||
| JP7597709B2 (ja) | 置換インドールおよびインダゾール化合物 | |
| JP2018508553A5 (enExample) | ||
| JP2012525367A5 (enExample) | ||
| JP2018512062A5 (enExample) | ||
| US20160108049A1 (en) | Novel Phthalazinone-Pyrrolopyrimidinecarboxamide Derivatives | |
| TW201305174A (zh) | 新穎呔嗪酮－吡咯并嘧啶甲醯胺衍生物 | |
| WO2015028848A1 (en) | Bicyclic heterocyclic compounds as multi-kinase inhibitors | |
| RU2024134125A (ru) | Новые соединения как ингибиторы надф-оксидазы |